亚洲免费av电影一区二区三区,日韩爱爱视频,51精品视频一区二区三区,91视频爱爱,日韩欧美在线播放视频,中文字幕少妇AV,亚洲电影中文字幕,久久久久亚洲av成人网址,久久综合视频网站,国产在线不卡免费播放

        ?

        Radiomics-clinical nomogram for response to chemotherapy in synchronous liver metastasis of colorectal cancer: Good, but not good enough

        2022-12-06 12:11:47HanYanTuNanYu
        World Journal of Gastroenterology 2022年9期

        Han Yan,Tu-Nan Yu

        Abstract There remains a persistent unmet need to detect the disease nonresponse (nonDR)subgroup before adjuvant therapy in synchronous liver metastasis patients with colorectal cancer. Ma’s radiomics-clinical nomogram shows potential for the early detection of nonDR subgroups, but it is not good enough owing to at least three limitaions, which we address in this letter to the editor. First, the study did not explore RAS/BRAF mutations, HER2 amplifications, etc. to complement the current nomogram. Second, the nomogram was not validated in left- and rightsided tumors separately. Third, the most critical factor for determining the success of adjuvant therapy should be resectability rather than tumor size shrinkage,which was used in the study.

        Key Words: Synchronous liver metastasis; Colorectal cancer; Radiomics

        TO THE EDITOR

        Maet al[1] recently published a novel study investigating the effect of magnetic resonance imagingradiomics in predicting chemotherapeutic response in synchronous liver metastasis (SLM) patients with colorectal cancer (CRC). They proposed a radiomics-clinical nomogram (including the radiomics score,CA19-9, and lymphatic staging) with an area under the curve of 0.809, suggesting high predictive accuracy.

        We congratulate the authors for their creative work, as in decision-making for adjuvant therapy in CRC patients with unresectable SLM, there remains a persistent unmet need to detect the disease nonresponse (nonDR) subgroup. Early detection of nonDR patients, aided by the radiomics-clinical nomogram of Ma’s study, could result in substantial changes in subsequent therapeutic plans. For instance, in nonDR cases, more aggressive regimens could be applied instead of the frequently used FOLFOX or CAPOX, such as administration of bevacizumab to inhibit vascular endothelial growth factor or pembrolizumab for immunotherapy. Local regional therapies, including radiofrequency ablation and transcatheter arterial chemoembolization,could also be considered to treat SLM.

        However, despite the aforementioned merit, there are at least three limitations to be discussed concerning this nomogram. First, although the authors explored tumor biomarkers, including CEA and CA19-9, to complement radiomics, the statuses of some critical tumor genes (e.g., RAS/BRAF mutations,HER2 amplification, and MSI/MMR status) were not examined, despite the relevant recommendation in the latest National Comprehensive Cancer Network guideline[2]. Second, it is noteworthy that the biological behaviors of CRC differed depending on the anatomical location[3]. For instance, right-sided CRC patients with SLM were unlikely to respond to cetuximab and panitumumab as first-line therapy.Therefore, the performance of Ma’s nomogram should be validated in right- and left-sided CRC separately. Last but not least, the most critical limitation was that the success of adjuvant therapy in CRC patients with SLM should be resectability, rather than tumor size shrinkage used in this study.

        In conclusion, in CRC patients with SLM, Ma’s radiomics-clinical nomogram shows potential for clinical utilization. However, it is currently not good enough.

        FOOTNOTES

        Author contributions:All authors helped to prepare this manuscript; Yan H and Yu TN contributed to manuscript writing, drafting conception and design.

        Conflict-of-interest statement:All authors declare that there are no conflicts of interest, and there was no fund

        supporting this manuscript.

        Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

        Country/Territory of origin:China

        ORCID number:Han Yan 0000-0001-8189-6678; Tu-Nan Yu 0000-0003-0866-3178.

        S-Editor:Gong ZM

        L-Editor:A

        P-Editor:Gong ZM

        中文字幕久久波多野结衣av不卡| 国产福利小视频91| 久久亚洲精品成人av观看| 国产精品国产av一区二区三区| 亚洲av无码乱码国产精品| 国产成人精品三级麻豆| 亚洲中文字幕精品久久久久久直播| 久久精品国产黄片一区| 国产日产亚洲系列最新| 国产成a人亚洲精v品无码性色| 2020国产精品久久久久| 中文字幕日韩精品永久在线| 丰满少妇作爱视频免费观看| 在线播放亚洲第一字幕| 最新国产美女一区二区三区| 在线观看国产一区二区av| 欧美人与禽2o2o性论交| 亚洲最大天堂无码精品区| 极品美女尤物嫩模啪啪| 在线观看麻豆精品视频| 午夜色大片在线观看| 亚洲色婷婷免费视频高清在线观看| 免费人成黄页网站在线观看国产| 手机在线观看日韩不卡av| 熟女体下毛毛黑森林| 国产成人8x视频网站入口| 日本免费一区二区在线| 国产精品无码dvd在线观看| 国产免费又色又爽又黄软件| 久久青青草视频免费观看| 亚洲精品有码日本久久久| 亚洲女初尝黑人巨高清 | 美女视频在线观看一区二区三区| 五月av综合av国产av| 中文字幕亚洲乱码熟女一区二区| 日本少妇爽的大叫高潮了| 丁香花五月六月综合激情| 精品人妻va出轨中文字幕| 最新欧美一级视频| 久久精品国产亚洲av久按摩| 亚洲精品久久久久久久不卡四虎|